8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) October 13, 2004

                             BSD MEDICAL CORPORATION
- --------------------------------------------------------------------------------
             (Exact name of registrant as specified in its charter)

          Delaware                       0-10783                 75-1590407
- --------------------------------------------------------------------------------
(State or other jurisdiction           (Commission            (I.R.S. Employer
      of incorporation)                File Number)          Identification No.)

               2188 West 2200 South
               Salt Lake City, Utah                                84119
- --------------------------------------------------------------------------------
      (Address of principal executive offices)                   (Zip Code)

        Registrant's telephone number, including area code (801) 972-5555

                                       N/A
- --------------------------------------------------------------------------------
         (Former name or former address, if changed since last report.)

Check  the  appropriate  box  below  if the  Form  8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written  communications  pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement  communications  pursuant  to  Rule  14d-2(b)  under  the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement  communications  pursuant  to  Rule  13e-4(c)  under  the
      Exchange Act (17 CFR 240.13a-4(c))




Item 7.01. Regulation FD Disclosure.

BSD Medical  Corporation  issued a press  release on October 13, 2004. A copy of
the press release is hereby  furnished as Exhibit 99.1 attached  hereto Pursuant
to the  requirements of the Securities  Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the  undersigned  hereunto
duly authorized.

Item 9.01. Financial Statements and Exhibits.

(c)   Exhibits

99.1  Press Release of BSD Medical Corporation dated October 13, 2004.




                                   SIGNATURES

      Pursuant to the  requirements of the Securities  Exchange Act of 1934, the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned hereunto duly authorized.

Dated: October 13, 2004

                                                       By: /s/ Hyrum A. Mead
                                                           -----------------
                                                           President

EX-99.1

                                                                    Exhibit 99.1

For Immediate Release
- ---------------------

        New Hyperthermia System by BSD Medical to Treat Pelvic Cancers in
                               2,400 Bed Hospital

      SALT LAKE CITY,  October 13, 2004--BSD  Medical Corp.  (OTCBB:BSDM)  today
announced that the Klinikum  Nuernberg,  a 2,400 bed,  community  owned teaching
hospital of the University Medical Center in Erlangen,  Germany, has installed a
new BSD-2000  hyperthermia  system to treat cancers in the pelvic area.  The new
system operates in the Department of Radiation  Oncology,  directed by Professor
Helmut Renner and Dr. Stefan Birkenhake.

      Klinikum  Nuernberg is known for its  cutting-edge  therapies  and for its
comprehensive care. Many of the treatments performed at the hospital are part of
national and  international  clinical studies in new cancer research,  including
clinical  trials  involving  ovarian,  colon and  breast  cancer.  Both the U.S.
National  Institute of Health (NIH) and the European  Organization  for Research
and Treatment of Cancer (EORTC) cite cancer research being conducted at Klinikum
Nuernberg.  The  hospital  maintains  extensive  archives of  documentation  and
scientific  publications  relating to cancer research and therapy,  and provides
information and counsel for cancer patients about treatment  options tailored to
their individual needs.

      Professor Renner, Director of the Department of Radiation Oncology,  said,
"We have  carefully  evaluated  the market and have chosen the  world's  leading
hyperthermia  system,  the BSD-2000,  together with the Hyperplan 2000 treatment
planning  system.  We have already accrued a long list of patients waiting to be
treated with hyperthermia therapy, and are pleased to begin treatments under the
protocols for pelvic diseases."

      The BSD-2000 focuses electromagnetic energy on cancerous tumors, including
tumors  located deep in the body,  giving the cancer an elevated  temperature of
108-111 degrees F (hyperthermia). Hyperthermia kills many cancer cells directly,
and causes tumors to uptake more blood, allowing chemotherapy drugs to be better
absorbed. Increasing the blood level in tumors also boosts the presence of water
and oxygen  necessary to form the  hydroxides  created by  radiation  therapy to
attack cancer cell DNA. Hyperthermia thereby reduces the resistance of cancer to
both radiation and chemotherapy. Clinical trials have demonstrated a substantial
improvement  in both cancer  response and long-term  survival when  hyperthermia
therapy is added to radiation, chemotherapy or both.

      BSD Medical Corporation is the leading developer of microwave systems used
in thermal medicine for the treatment of cancer.  For more information about BSD
Medical Corp. visit www.BSDMC.com.

      Statements  contained in this press release that are not historical  facts
are  forward  looking  statements,  as  that  item  is  defined  in the  Private
Securities  Litigation  Reform Act of 1995. All  forward-looking  statements are
subject to risks and  uncertainties,  some of which are  detailed in part in the
Company's filings with the Securities and Exchange Commission.